• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Earns 2025 Great Place To Work® Certification™

    5/12/25 10:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email

    Award marks seventh consecutive year company has received prestigious distinction

    Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany.

    The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and leadership. This year, 77% of employees called Exact Sciences a Great Place To Work – 20 points higher than the average U.S.-based company. Great Place To Work is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation.

    "Exact Sciences is proud to be recognized as a Great Place To Work for the seventh year in a row—an honor that reflects the passion, integrity, and drive for innovation of our incredible team," said Sarah Condella, executive vice president of human resources at Exact Sciences. "Our purpose of eradicating cancer guides everything we do, and we're committed to creating a workplace where everyone feels respected, included, and empowered."

    By achieving this distinction, Exact Sciences joins an elite group of organizations that have demonstrated exceptional workplace practices, a willingness to act on employee feedback, and a strong commitment to employee well-being. The anonymous feedback collected during certification focuses on factors known to impact the quality of an employee's experience, such as trust, pride, respect, and camaraderie.

    "Great Place To Work Certification is a highly coveted achievement that requires consistent and intentional dedication to the overall employee experience," says Sarah Lewis-Kulin, the Vice President of Global Recognition at Great Place To Work. She emphasizes that Certification is the sole official recognition earned by the real-time feedback of employees regarding their company culture. "By successfully earning this recognition, it is evident that Exact Sciences stands out as one of the top companies to work for, providing a great workplace environment for its employees."

    According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a certified great workplace and 15 times more likely to choose to work at a certified great workplace. Additionally, employees at certified workplaces are 93% more likely to look forward to coming to work and are twice as likely to be paid fairly, to earn a fair share of the company's profits, and to have a fair chance at promotion.

    Exact Sciences is looking for talented people who are passionate about fighting cancer. For more information and to view a complete list of job openings, visit the company careers site.

    About Exact Sciences Corp.

    A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X (formerly known as Twitter) @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

    NOTE: Exact Sciences and Cologuard are trademarks of Exact Sciences Corporation. Oncotype is a trademark of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences.

    About Great Place To Work® Certification™

    Great Place To Work® Certification™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place To Work-Certified.

    About Great Place To Work®

    As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at greatplacetowork.com and follow Great Place To Work on LinkedIn, Twitter, Facebook and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250512833110/en/

    Media Contact (U.S.):

    Blair Brophy

    +1 608-630-7391

    [email protected]



    Investor Contact:

    Derek Leckow

    608-893-0009

    [email protected]

    Get the next $EXAS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    More analyst ratings

    $EXAS
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Exact Sciences Corporation

      S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)

      7/11/25 4:06:24 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Exact Sciences Corporation

      S-8 - EXACT SCIENCES CORP (0001124140) (Filer)

      7/11/25 4:02:07 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Exact Sciences Corporation

      11-K - EXACT SCIENCES CORP (0001124140) (Filer)

      6/24/25 4:01:22 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Doyle James Edward was granted 5,398 shares, increasing direct ownership by 10% to 61,447 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:22 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Popovits Kimberly J was granted 9,994 shares, increasing direct ownership by 156% to 16,381 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:15 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Barber Michael J was granted 7,197 shares, increasing direct ownership by 121% to 13,136 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:20 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Exact Sciences with a new price target

      Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

      4/10/25 12:41:36 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

      RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

      3/13/25 7:36:02 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Exact Sciences with a new price target

      Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00

      1/23/25 7:42:29 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period. The final LCD can be found here, and the billing and coding article here, from CMS. This marks a significant milestone in the company's mission to transform cancer treatment through earlier detection and more personalize

      7/9/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap

      Beta-CORRECT study to be presented at ASCO 2025 confirms the clinical utility of the molecular residual disease (MRD) test, Oncodetect™, for recurrence monitoring in stage II–IV colorectal cancer Whole-genome Oncodetect test powered by MAESTRO to launch in 2026 with ultra-low limit of detection1 Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data to be presented from the Beta-CORRECT clinical validation study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Results from Beta-CORRECT, a subset of the GALAXY cohort, validate the performance of its tumor-informed molecular residual disease (MRD) t

      5/28/25 6:05:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences to Participate in June Investor Conference

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. William Blair 45th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 3, 2025 at 9:40 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success o

      5/27/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      11/13/24 2:58:53 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      11/8/24 10:52:39 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      10/7/24 11:37:08 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

      Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl

      7/25/24 8:00:00 AM ET
      $EXAS
      $PODD
      Medical Specialities
      Health Care
      Medical/Dental Instruments

    $EXAS
    Financials

    Live finance-specific insights

    See more
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules First Quarter 2025 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod

      4/1/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Fourth Quarter 2024 Results

      Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic

      2/19/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care